NASDAQ:ADVM - Adverum Biotechnologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.05 +0.30 (+5.22 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$6.05
Today's Range$5.60 - $6.10
52-Week Range$2.40 - $8.59
Volume6.28 million shs
Average Volume520,143 shs
Market Capitalization$358.06 million
P/E Ratio-4.69
Dividend YieldN/A
Beta3.62
Adverum Biotechnologies logoAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269

Debt

Debt-to-Equity RatioN/A
Current Ratio26.88
Quick Ratio26.88

Price-To-Earnings

Trailing P/E Ratio-4.69
Forward P/E Ratio-4.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.85 million
Price / Sales203.64
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,571.30%
Return on Equity-28.51%
Return on Assets-26.45%

Miscellaneous

Employees78
Outstanding Shares62,270,000

The Truth About Cryptocurrencies

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) issued its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.40 million. Adverum Biotechnologies had a negative return on equity of 28.51% and a negative net margin of 3,571.30%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

3 brokerages have issued 12 month price targets for Adverum Biotechnologies' shares. Their predictions range from $3.50 to $12.00. On average, they anticipate Adverum Biotechnologies' share price to reach $7.1667 in the next year. View Analyst Ratings for Adverum Biotechnologies.

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (5/22/2018)
  • 2. Chardan Capital analysts commented, "We note PRVs have in 2017 sold for: 1) $130 mm to Ultragenyx Pharmaceutical (unrated), announced 18 December 2017; 2) $125 mm to BioMarin Pharmaceutical (unrated), announced 27 November 2017, and 3) $125 mm to Sarepta Therapeutics (unrated), announced 21 February 2017. We understand Spark will announce the pricing of Luxturna in January, and that the drug will be available in late 1Q18. The Midwest CEPAC will convene to discuss the Institute for Clinical and Economic Review (ICER) document on Luxturna, on 25 January 2018. Luxturna’s approval is an important (+) for GT, particularly for AAV-based ophthalmology companies. We understand Luxturna is the first gene therapy approved in the US for a genetic disease, the first in vivo and AAV-based gene therapy approved in the US, and the first pharmacologic treatment approved for an inherited retinal disease (IRD)." (12/19/2017)

Who are some of Adverum Biotechnologies' key competitors?

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Mr. Paul B. Cleveland, Chairman (Age 61)
  • Dr. Amber Salzman Ph.D., Chief Exec. Officer, Pres and Director (Age 56)
  • Dr. Mitchell H. Finer Ph.D., Co-Founder and Director (Age 59)
  • Dr. Mehdi Gasmi Ph.D., Chief Science and Technology Officer (Age 51)
  • Ms. Leone D. Patterson, Chief Financial Officer (Age 55)

Has Adverum Biotechnologies been receiving favorable news coverage?

News coverage about ADVM stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adverum Biotechnologies earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.24 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (3.21%), Millennium Management LLC (2.68%), Alkeon Capital Management LLC (2.40%), Dimensional Fund Advisors LP (1.89%), Rock Springs Capital Management LP (1.45%) and BlackRock Inc. (1.11%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Adverum Biotechnologies.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alkeon Capital Management LLC, Millennium Management LLC, Rock Springs Capital Management LP, Nexthera Capital LP, Artal Group S.A., BlackRock Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $6.05.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $358.06 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (ADVM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  364
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.